Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Monica Bertagnolli

Surgical Oncology · Harvard Medical School

View

Dr. Philip Schauer

Bariatric Surgery · PBRC

View

Dr. Todd Rosengart

Cardiac Surgery · BCM

View

Dr. Larry Kaiser

Thoracic Surgery · UPenn

View

Dr. Neri Cohen

Thoracic Surgery · XVIVO

View

Dr. Jad M Abdelsattar, M.D, FACS

Breast Surgical Onc · University of Oxford

View

Dr. Lauren Kopicky

Breast Surgical Onc · Cleveland Clinic

View

Dr. Jennifer Plichta

Breast Surgical Onc · Duke University

View

Dr. Sarah Blair

Breast Surgical Onc · UCSD

View

Dr. Karen Goodwin

Breast Surgical Onc · UCSF

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    The Utility of Preoperative PET/CT in Patients with Clinically High-Risk Melanoma.

    Sep 25, 2025DOI: 10.1245/s10434-025-18096-wJournal ArticleASO

    Written by: Emily PapaiKayla NtohLi ZhangJian Q YuAnthony J OlszanskiAnthony M VillanoAndrea S PorpigliaSanjay S ReddyJeffrey M FarmaStephanie H Greco

    Find these authors on Roon

    JF
    Dr. Jeffrey Farma
    Surgical Oncology · Fox Chase Cancer Center

    Summary

    BACKGROUND: Melanoma is a lethal skin cancer and accounts for the highest mortality rate caused by cutaneous malignancies. Prognosis is dependent on stage. Patients with "thick" melanomas of 4-mm Breslow depth or greater are at increased risk for nodal metastases. Positron emission tomography/computed tomography (PET/CT) may be an underutilized imaging study for preoperative clinical staging in those with T4 melanoma.PATIENTS AND METHODS: This was a single-institution retrospective analysis of adult patients with biopsy-proven T4 predominantly cutaneous melanoma (> 4 mm tumor thickness) who underwent preoperative PET/CT at a single National Cancer Institute (NCI)-designated cancer center between 1 January 2010 and 30 December 2022. Patients were excluded if there was clinical evidence of locoregional or distant metastatic disease at time of preoperative PET/CT.RESULTS: A total of 94 patients met inclusion criteria. They were predominantly male (n = 56, 59.6%) and Caucasian (n = 83, 94.3%) with an average body mass index (BMI) of 27.97 and median age of 69.5 years. A total of 69.7% of patients had tumor ulceration on biopsy and 2% had microsatellitosis. Positive PET/CT scans were found in eight patients (8.5%), which changed clinical management in seven of the eight patients. When comparing PET/CT results to sentinel lymph node biopsy (SLNB) results, sensitivity was 15.4%, specificity was 94.1%, positive predictive value was 50%, and negative predictive value was 74.4%.CONCLUSIONS: Patients with T4 melanoma without clinical suspicion of nodal disease do not have a high rate of occult metastases on preoperative PET/CT. We argue that clinical exam remains the most important tool for preoperative workup in these patients, but that PET/CT may be considered on the basis of patient-specific factors.
    JFDr. Jeffrey Farma

    Dr. Jeffrey Farma

    Surgery · Surgical Oncology
    Fox Chase Cancer Center
    jeffreyf